Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer

Nivolumab is a humanized IgG4 and programmed death 1 (PD-1) monoclonal antibody that has demonstrated antitumor efficacy in clinical trials of various malignant tumors including non-small-cell lung cancer and head and neck squamous cell carcinoma (SCC). However, patients with multiple primary malign...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Teppei, Sakurai, Kazuo, Kuroda, Makoto, Imaizumi, Kazuyoshi, Hida, Toyoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649270/
https://www.ncbi.nlm.nih.gov/pubmed/29070993
http://dx.doi.org/10.1159/000479960

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649270/
https://www.ncbi.nlm.nih.gov/pubmed/29070993
http://dx.doi.org/10.1159/000479960

Ejemplares similares